article thumbnail

BioSpace Global Roundup: Ipsen Wins Fast Track Designation for Cancer Drug and More

The Pharma Data

aeruginosa bacteria, instead of killing the bacteria as an antibiotic would aim to do. The license from ERS Genomics now enables Vivlion to offer both R&D reagents and screening services to its customers worldwide. The new “pathoblocker” treatment aims to disarm pathogens and suppress the disease-causing properties of P.

Drugs 52
article thumbnail

Biopharma Update on the Novel Coronavirus: October 20

The Pharma Data

DB ( Becton, Dickinson and Company ) received a CE mark for its BD Multitest 6-Color TBNK Reagent with BD Trucount Tubes for assessing immune function in COVID-19 patients. In a challenge trial, people are given a vaccine then intentionally dosed with the virus or bacteria that causes the disease.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Rising Demand for DNA and Gene Cloning  Service Providers

Roots Analysis

Further, the labor and reagent cost incurred in cloning procedures is reduced with customized cloning. Along with this, the high quality DNA clones and gene clones are customized as per the need and requirement. Genetic Synthesis: It includes in-vitro synthesis of any DNA sequence or gene without the involvement of initial template.

DNA 40
article thumbnail

BioSpace Global Roundup, Oct. 15

The Pharma Data

Under the terms of the non-exclusive agreement FASMAC acquires the right to use CRISPR/Cas9 technology and commercialize tools and reagents associated with it. CARB-X will provide Polyphor with initial funding of up to $2.62 million to complete the hit-to-lead stage and up to USD 15.82 million if certain project milestones are met.

article thumbnail

Emerging Trends in Protein Expression Systems: Growth Opportunities And Future Outlook

Roots Analysis

Transformation / Transfection: The expression vector is introduced into the host organism (bacterial, yeast, insect, algal, cell-free or mammalian cells) through transformation (for bacteria and yeast) or transfection (for mammalian cells).

Protein 40
article thumbnail

Global Roundup: EU Approves ViiV’s HIV-1 Drug and More

The Pharma Data

The agreement includes a £500,000 upfront payment to Avacta which gives Astrea the rights to generate and develop Affimer reagents in-house for affinity separation. Astrea is a leading provider of affinity separation solutions to the pharmaceutical and biomanufacturing industries. It is a division of Gamma Biosciences.

Drugs 52